Inspirion Wealth Advisors LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Inspirion Wealth Advisors LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 24.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,031 shares of the biopharmaceutical company's stock after acquiring an additional 12,644 shares during the period. Inspirion Wealth Advisors LLC's holdings in Pfizer were worth $1,623,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $30,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PFE shares. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Price Performance

Pfizer stock traded down $0.09 during mid-day trading on Tuesday, hitting $23.37. The stock had a trading volume of 35,434,503 shares, compared to its average volume of 41,046,415. The firm has a market capitalization of $132.85 billion, a P/E ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm's 50 day moving average is $23.08 and its 200 day moving average is $25.04. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm posted $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.36%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.